Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis

Inclusion Criteria: * History of hospitalization for COVID-19 infection documented with positive PCR or positive serology in the previous 2 to 12 months * Lung opacities on HRCT involving more than 10% of the lung volume, with fibrotic features * DLCO≤ 70% of the predicted value Exclusion Criteria: * Pre-existing lung disorder with abnormal HRCT (including COPD, lung cancer, or pulmonary fibrosis) * Laboratory parameter thresholds: * renal insufficiency with following criteria: Creatinine clearance \<30 ml/min estimated by the Cockcroft-Gault equation. * any of the following liver test criteria above the specified limit: Total bilirubin \> 1.5 above the upper limit of the normal range (ULN), except in patients with predominantly unconjugated hyperbilirubinemia (e.g., Gilbert's syndrome). Aspartate or alanine aminotransferase (AST or ALT) \>3 × ULN (refer to the protocol, Table 3 p 34 for the management of liver enzyme elevation). * Recent surgery with wound healing in progress(\<7days ) * Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment). * Significant pulmonary arterial hypertension (PAH) defined by any of the following: 1. Previous clinical or echocardiographic evidence of significant right heart failure 2. History of right heart catheterisation showing a cardiac index ≤2 L/min/m² 3. PAH requiring parenteral therapy with epoprostenol/treprostinil. * History of cardiovascular diseases, any of the following: 1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of Visit 1 2. Myocardial infarction within 6 months of Visit 1 3. Unstable cardiac angina within 6 months of Visit 1. * Bleeding risk, any of the following: 1. Known genetic predisposition to bleeding. 2. Patients who require i. Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin) ii. High dose antiplatelet therapy. * Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment. * Ongoing or past antifibrotic treatment with pirfenidone or nintedanib * Hypersensitivity to nintedanib, peanut or soya or to any of the excipients of the specialty Ofev® * Patients not able to understand and follow study procedures including completion of self-administered questionnaires without help. * No written informed consent from the patient * Absence of affiliation to the French social security * Participation in another interventional research